tirzepatide novo nordisk sues Eli Lilly for false advertising over weight loss drug comparisons. Get the details Lilly goes toe-to-toe with Novo

Retatrutide's GLP-1 affinity is the floor of the stack most of the early appetite suppression in the first 4-8 weeks is reportedly GLP-1-mediated

2016;11(2):e0148899

Rates of gout were also slightly higher - 7.4 per cent for GLP-1 users versus 6.6 per cent for nonusers, an increased risk of about 12 per cent

Research shows that consistent weekly injections produce more stable appetite suppression and metabolic effects than irregular schedules

Health care professionals typically treat overweight and obesity by combining lifestyle changes with medication when lifestyle changes alone are not enough, and by reassessing whether a medicine is working before continuing it (NIDDK guidance on treating adult overweight and obesity)

PMID: 32969946